TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15265537

Group type: COMPARATOR
Intervention: Neutrophils from astronauts after 5-day mission
Number of subjects: 34

Group type: COMPARATOR
Intervention: Neutrophils from astronauts after 9- to 11-day missions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Neutrophils from astronauts before and after space missions
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Neutrophils from astronauts at landing
Number of subjects: 34
Study: 11679455

Group type: EXPERIMENTAL
Intervention: Standard group received insulin treatment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Experimental group received insulin if AC >70th percentile and/or FPG >120 mg/dl
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Experimental group (infants of women who did not receive insulin)
Number of subjects: 98
Study: 9447368

Group type: EXPERIMENTAL
Intervention: Dihydralazine (5 mg, repeated every 20 min up to 4 doses)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketanserin (10 mg, repeated every 20 min up to 4 doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 80
Study: 8199822

Group type: EXPERIMENTAL
Intervention: Alkali citrate therapy (group II, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General prophylactic instructions (group I, n = 25)
Number of subjects: 50
Study: 3266072

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Sham machines (Control)
Number of subjects: 280
Study: 29630549

Group type: EXPERIMENTAL
Intervention: Propolis (0.83 g, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 60
Study: 26562046

Group type: EXPERIMENTAL
Intervention: SBP goal of <120 mm Hg
Number of subjects: 16800000

Group type: EXPERIMENTAL
Intervention: Treated hypertension
Number of subjects: 16800000

Group type: EXPERIMENTAL
Intervention: Overall U.S. population
Number of subjects: 16800000

Group type: EXPERIMENTAL
Intervention: Age and gender
Number of subjects: 16800000

Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 16800000

Group type: EXPERIMENTAL
Intervention: Untreated hypertension
Number of subjects: 16800000
Study: 25203483

Group type: EXPERIMENTAL
Intervention: One-sample FIT kit (1-FIT)
Number of subjects: 3081

Group type: COMPARATOR
Intervention: Two-sample FIT kit (2-FIT)
Number of subjects: 3081
Study: 24068048

Group type: EXPERIMENTAL
Intervention: High-intensity constant-power exercise with 18 s recovery
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-intensity constant-power exercise with 30 s recovery
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-intensity constant-power exercise with 48 s recovery
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All intermittent protocols
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recovery of intramuscular phosphocreatine concentration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: W>CP in excess of W'
Number of subjects: 9
Study: 21417560

Group type: EXPERIMENTAL
Intervention: Continuous COC (levonorgestrel [LNG] 90 μg/ethinylestradiol [EE] 20 μg)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cyclic COC (LNG 100 μg/EE 20 μg, 21/7 days pattern)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Continuous COC
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cyclic COC
Number of subjects: 147
Study: 18344728

Group type: EXPERIMENTAL
Intervention: 15 mg temazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16988930

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study: 14680092

Group type: EXPERIMENTAL
Intervention: Dithiothreitol-formaldehyde mixture for 48-72 h before dispersal with trypsin (preservation method)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine method using dithiothreitol
Number of subjects: 39
Study: 10764175

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands applied at P6 points
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group with wristbands placed inappropriately on the posterior surface
Number of subjects: 200
Study: 9214817

Group type: EXPERIMENTAL
Intervention: Tracking tasks with visuoperceptual buffer-zone technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nonmotor test of dynamic visuoperception
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 32
Study: 1486675

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether plus oral mefloquine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate plus oral mefloquine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Intravenous quinine plus oral tetracycline
Number of subjects: 141
Study: 7011353

Group type: EXPERIMENTAL
Intervention: Amoxycillin 250 mg or 500 mg, orally three times daily for seven days
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Ampicillin 250 mg or 500 mg, orally three times daily for seven days
Number of subjects: 199

Group type: COMPARATOR
Intervention: Amoxycillin and Ampicillin (both doses)
Number of subjects: 199
Study: 31245842

Group type: EXPERIMENTAL
Intervention: Baseline screening for high-risk HPV
Number of subjects: 19509

Group type: EXPERIMENTAL
Intervention: Baseline HPV negative women
Number of subjects: 19509

Group type: COMPARATOR
Intervention: Control group (LBC)
Number of subjects: 19509

Group type: EXPERIMENTAL
Intervention: Intervention group (HPV)
Number of subjects: 19509

Group type: EXPERIMENTAL
Intervention: HPV negative at exit
Number of subjects: 19509
Study: 30859185

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 or 200 μg/kg for PSAC; 200, 400 or 600 μg/kg for SAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 μg/kg)
Number of subjects: 0
Study: 28422532

Group type: EXPERIMENTAL
Intervention: FP(100) - 100% fast protein
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FP(50) - 50% fast and 50% slow proteins
Number of subjects: 31

Group type: COMPARATOR
Intervention: FP(20) - 20% fast protein and 80% casein
Number of subjects: 31
Study: 23020829

Group type: EXPERIMENTAL
Intervention: Routine iron group (n=2184) received 60 mg of ferrous sulphate plus 400 μg of folic acid daily
Number of subjects: 4326

Group type: COMPARATOR
Intervention: Selective iron group (n=2142) had screening and treatment for anaemia and a daily intake of 1 mg of folic acid
Number of subjects: 4326
Study: 23543344

Group type: EXPERIMENTAL
Intervention: 30 minutes of 120 Hz segmental muscle vibration over the rectus femoris and gastrocnemius medial and lateral, three per week, over a period of four weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: botulinum toxin in the rectus femoris, gastrocnemius medial and lateral and soleus, and segmental muscle vibration
Number of subjects: 42

Group type: COMPARATOR
Intervention: botulinum toxin
Number of subjects: 42
Study: 20094773

Group type: EXPERIMENTAL
Intervention: erlotinib 150 mg/day
Number of subjects: 1079

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: erlotinib
Number of subjects: 1079
Study: 20031753

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 324

Group type: COMPARATOR
Intervention: Iomeprol
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Iodixanol (high contrast volume)
Number of subjects: 324
Study: 16805715

Group type: EXPERIMENTAL
Intervention: Rituximab added to chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation
Number of subjects: 0
Study: 16827869

Group type: COMPARATOR
Intervention: TAS (tacrolimus/azathioprine/steroids)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: TAS + B (tacrolimus/azathioprine/steroids/basiliximab)
Number of subjects: 192
Study: 12810426

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid injections (2 ml prednisolone acetate 50 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Isotonic saline (2 ml)
Number of subjects: 85
Study: 10198663

Group type: EXPERIMENTAL
Intervention: Tailored written information
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Standard written information
Number of subjects: 763

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 763
Study: 7597125

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (T-)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tryptophan enhancement (T+)
Number of subjects: 48
Study: 2194466

Group type: EXPERIMENTAL
Intervention: ibuprofen plus a rib belt
Number of subjects: 20

Group type: COMPARATOR
Intervention: ibuprofen
Number of subjects: 20
Study: 7000292

Group type: EXPERIMENTAL
Intervention: Hormonal treatment (stilboestrol and ethisterone)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Inactive tablets (control group)
Number of subjects: 156
Study: 30541552

Group type: COMPARATOR
Intervention: Low- and middle-income groups
Number of subjects: 14262

Group type: COMPARATOR
Intervention: Low-income groups
Number of subjects: 14262

Group type: COMPARATOR
Intervention: High-income groups
Number of subjects: 14262
Study: 28074635

Group type: EXPERIMENTAL
Intervention: Active arm participants received pedometers and recorded step counts with physician monitoring and prescriptions; goal was a 3000 steps/day increase over 1 year.
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Active arm participants (not treated with insulin)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control arm participants were advised to engage in physical activity 30 to 60 min/day.
Number of subjects: 347
Study: 26178653

Group type: EXPERIMENTAL
Intervention: Verbal creativity training (20 min per day for 3 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (time-delayed training)
Number of subjects: 53
Study: 23005579

Group type: EXPERIMENTAL
Intervention: Implementation intentions (IIs)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Common intervention activities
Number of subjects: 101
Study: 21365308

Group type: EXPERIMENTAL
Intervention: Resonance frequency HRV biofeedback (10 weekly sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resonance frequency HRV biofeedback
Number of subjects: 24
Study: 18164106

Group type: EXPERIMENTAL
Intervention: Co-administered quadrivalent HPV-6/11/16/18 L1 VLP and HBV vaccines
Number of subjects: 1877
Study: 16879458

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 12826431

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus platinum chemotherapy
Number of subjects: 802

Group type: COMPARATOR
Intervention: Conventional platinum-based chemotherapy
Number of subjects: 802
Study: 10921706

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (200 IU/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (300 IU/kg heparin)
Number of subjects: 23
Study: 8888725

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (5.1 g/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 1796780

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1,600 micrograms
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6138302

Group type: EXPERIMENTAL
Intervention: LH-RH treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: HCG treatment
Number of subjects: 0
Study: 31416171

Group type: EXPERIMENTAL
Intervention: Intact protein preterm formula (IPF)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 65
Study: 28091445

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Control group (no dexmedetomidine)
Number of subjects: 3600
Study: 25640764

Group type: EXPERIMENTAL
Intervention: Escalating reinforcement schedule
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Fixed reinforcement schedule
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 146
Study: 24380609

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 132
Study: 22639376

Group type: EXPERIMENTAL
Intervention: Anterior 90° partial fundoplication
Number of subjects: 79

Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 79
Study: 18989343

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tetracaine 1% drops
Number of subjects: 40
Study: 17470851

Group type: EXPERIMENTAL
Intervention: FLOX (Fluorouracil 500 mg/m2 IV bolus weekly for 6 weeks + Leucovorin 500 mg/m2 IV weekly for 6 weeks + Oxaliplatin 85 mg/m2 IV on weeks 1, 3, and 5 for three cycles)
Number of subjects: 2407

Group type: COMPARATOR
Intervention: FULV (Fluorouracil 500 mg/m2 IV bolus weekly for 6 weeks + Leucovorin 500 mg/m2 IV weekly for 6 weeks for three cycles)
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: FLOX
Number of subjects: 2407

Group type: COMPARATOR
Intervention: FLOX and FULV
Number of subjects: 2407
Study: 15472674

Group type: EXPERIMENTAL
Intervention: Bowel preparation with 2 L of polyethylene glycol/electrolyte solution (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clear liquids preparation (Group B)
Number of subjects: 80
Study: 11159252

Group type: EXPERIMENTAL
Intervention: Epidural block with 7 mL 1% lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural injection of an identical volume of normal saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: IV injection of 1 mg/kg lidocaine
Number of subjects: 30
Study: 9355788

Group type: EXPERIMENTAL
Intervention: Acetorphan (oral administration prior to cholera toxin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cholera toxin alone (control group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetorphan (oral administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Basal conditions (without acetorphan or cholera toxin)
Number of subjects: 10
Study: 8297542

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/day)
Number of subjects: 2598

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 2598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2598

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2598
Study: 3443128

Group type: EXPERIMENTAL
Intervention: Molsidomin 8 mg (slow release form)
Number of subjects: 2

Group type: COMPARATOR
Intervention: ISDN 40 mg (slow release form)
Number of subjects: 2
Study: 31246109

Group type: COMPARATOR
Intervention: Mean arterial pressure <70 mmHg
Number of subjects: 657

Group type: COMPARATOR
Intervention: Mean arterial pressure 70-80 mmHg
Number of subjects: 657

Group type: COMPARATOR
Intervention: Mean arterial pressure >80 mmHg
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Survivors with impaired cognitive function (n=132, 35%)
Number of subjects: 657
Study: 29459229

Group type: EXPERIMENTAL
Intervention: Check & Connect (C&C) intervention for two years
Number of subjects: 345
Study: 27641921

Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery (retropubic or transobturator)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 293
Study: 23527517

Group type: EXPERIMENTAL
Intervention: Own-face appearance-based intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Generic appearance-based intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Information-only
Number of subjects: 46
Study: 22434058

Group type: EXPERIMENTAL
Intervention: Fluid filled intra-uterine extra-amniotic Foley catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: 25 microgram misoprostol vaginally every 4 h
Number of subjects: 100
Study: 20684724

Group type: EXPERIMENTAL
Intervention: 2 doses of RIX4414
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: 3 doses of RIX4414
Number of subjects: 475

Group type: COMPARATOR
Intervention: 3 doses of placebo
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: RIX4414 (2 doses and 3 doses)
Number of subjects: 475
Study: 18240018

Group type: EXPERIMENTAL
Intervention: Biofeedback combined with a specific respiratory pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other respiratory patterns
Number of subjects: 0
Study: 15860685

Group type: EXPERIMENTAL
Intervention: Isometric knee extensor peak torque
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Concentric-slow knee extensor peak torque
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Quadriceps femoris cross-sectional area
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Leg lean mass
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Type I fiber area
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Type IIa fiber area
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Type IIx fiber area
Number of subjects: 27
Study: 14522473

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1018
Study: 10999014

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/kg per min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study: 8820253

Group type: EXPERIMENTAL
Intervention: Inhaled nitroglycerin (NTG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 mu g MDI) after NTG
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled salbutamol (200 mu g MDI) after placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: FEV1 after 15 min post-treatment
Number of subjects: 10
Study: 2206108

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 20
Study: 7030121

Group type: EXPERIMENTAL
Intervention: Lignocaine 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 100
Study: 31752370

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10 (3 × 10^10 CFU)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10 (9 × 10^10 CFU)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 29973970

Group type: EXPERIMENTAL
Intervention: Collagen (2 ml of collagen MD Muscle)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 ml of 2% lidocaine without a vasoconstrictor)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (2 ml of 0.9% NaCl)
Number of subjects: 43
Study: 27861663

Group type: EXPERIMENTAL
Intervention: β‐TCP plus PRP (study group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: β‐TCP alone (control group)
Number of subjects: 18
Study: 24094754

Group type: EXPERIMENTAL
Intervention: Intoxicating dose of alcohol (.8 g/kg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 104
Study: 22651986

Group type: EXPERIMENTAL
Intervention: Telephone case monitoring (TCM)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Face-to-face continuing care as usual (CCAU)
Number of subjects: 667
Study: 20530650

Group type: EXPERIMENTAL
Intervention: Ultrasound plus exercise (group 1, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sham ultrasound plus exercise (group 2, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No exercise - no treatment (control group, n = 15)
Number of subjects: 45
Study: 18826778

Group type: EXPERIMENTAL
Intervention: Intervention group (improved identification, diagnosis, and treatment of depression)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 145
Study: 15821692

Group type: EXPERIMENTAL
Intervention: Twin-block (TB) appliance
Number of subjects: 70

Group type: COMPARATOR
Intervention: mini-block (MB) appliance
Number of subjects: 70
Study: 12235695

Group type: EXPERIMENTAL
Intervention: Instillagel
Number of subjects: 59

Group type: COMPARATOR
Intervention: 2% Lignocainum hydrochloricum (Control)
Number of subjects: 59
Study: 10661008

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8571641

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of dipyridamole prior to PTCA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole infusion during coronary angiography
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pretreatment
Number of subjects: 20
Study: 2300793

Group type: EXPERIMENTAL
Intervention: Glass-ionomer lining cement etched (group A)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glass-ionomer lining cement unetched (group B)
Number of subjects: 9
Study: 384574

Group type: EXPERIMENTAL
Intervention: Intra-arterial hepatic artery infusion with 5-fluorouracil (5-FU)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Systemic chemotherapy with 5-fluorouracil (5-FU)
Number of subjects: 74
Study: 6813477

Group type: EXPERIMENTAL
Intervention: Auranofin 2 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg daily
Number of subjects: 0
Study: 30673750

Group type: EXPERIMENTAL
Intervention: Independent older people (EAT-10 score ≥3)
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Dependent older people (EAT-10 score ≥3)
Number of subjects: 1396
Study: 29733414

Group type: COMPARATOR
Intervention: CON (no supplemental Zn)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: ZnAA0 (60 mg Zn/kg from ZnSO4)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: ZnAA60 (60 mg Zn/kg from ZnAA)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: ZnAA90 (90 mg Zn/kg from ZnAA)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: ZnAA120 (120 mg Zn/kg from ZnAA)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: ZnAA150 (150 mg Zn/kg from ZnAA)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: All ZnAA treatments (ZnAA0, ZnAA60, ZnAA90, ZnAA120, ZnAA150)
Number of subjects: 288
Study: 26562367

Group type: EXPERIMENTAL
Intervention: Caffeine (discontinued)
Number of subjects: 50
Study: 25319764

Group type: EXPERIMENTAL
Intervention: CareToy training for four weeks, customized by rehabilitation staff.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 40